✦ LIBER ✦

920 Adalimumab Maintains Long-Term Remission in Moderately to Severely Active Crohn's Disease After Infliximab Failure: 1-Year Follow-Up of Gain Trial

✍ Scribed by Remo Panaccione; William J. Sandborn; Geert D'Haens; Robert A. Enns; Douglas C. Wolf; Kathleen G. Lomax; Paul F. Pollack

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P006 ADALIMUMAB MAINTAINS LONG-TERM REMI

✍ R. Panaccione; W.J. Sandborn; G.R. D'Haens; R. Enns; D.C. Wolf; K.G. Lomax; P.F. 📂 Article 📅 2008 🏛 Oxford University Press ⚖ 92 KB

922 Adalimumab Maintains Long-Term Remis

✍ Remo Panaccione; Jean-Frédéric Colombel; William J. Sandborn; Paul Rutgeerts; Ge 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 173 KB

P148 - Adalimumab maintains long-term re

✍ R. Panaccione; J.F. Colombel; W.J. Sandborn; P. Rutgeerts; G. D'Haens; K.G. Loma 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 61 KB

W1092 Maintenance of Long-Term Remission

✍ Rutgeerts, Paul; Colombel, Jean-Frederic; Sandborn, William J.; Rutgeerts, Paul 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 99 KB